Skip to main content

Advertisement

Table 2 Number of small-bowel mucosal injuries and CE scores upon initial and follow-up CE in the polaprezinc treatment group and non-polaprezinc (control) group

From: Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study

  Initial CE Follow-up CE Pvalue
Polaprezinc group (n = 10)    
 Median number of erosions/ulcers (range) 2 (0-6) 0 (0-4) 0.039*
 Median number of reddened lesions (range) 3 (0-7) 1 (0-1) 0.003*
 Median CE score (range) 180 (0-450) 0 (0-225) N.S.*
 CE score by category    
 Normal or clinical insignificant change (<135) 3 6  
 Mild change (≥135 and <790) 7 4 N.S.**
 Moderate or severe change (≥790) 0 0  
Control group (n = 10)    
 Median number of erosions/ulcers (range) 2 (0-10) 0 (0-9) N.S.*
 Median number of reddened lesions (range) 2 (0-7) 2 (0-7) N.S.*
 Median CE score (range) 225 (0-225) 0 (0-450) N.S.*
 CE score by category    
 Normal or clinically insignificant change (<135) 4 6  
 Mild change (≥135 and <790) 6 4 N.S.**
 Moderate or severe change ((≥790) 0 0  
  1. Abbreviations: CE, Capsule endoscopy; N.S., Not significant.
  2. *by Wilcoxon signed-rank test **by Fisher’s exact test.